The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.
The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.
复制标题
DOI：
10.1016/j.jalz.2011.03.005
复制
发表时间：
2011-05
期刊：
影响因子：
--
通讯作者：
Phelps CH
中科院分区：
文献类型：
--
作者：
McKhann GM;Knopman DS;Chertkow H;Hyman BT;Jack CR Jr;Kawas CH;Klunk WE;Koroshetz WJ;Manly JJ;Mayeux R;Mohs RC;Morris JC;Rossor MN;Scheltens P;Carrillo MC;Thies B;Weintraub S;Phelps CH
美国国家老龄化研究所和阿尔茨海默氏症协会委托一位专家负责修订1984年阿尔茨海默氏症（AD）痴呆症的标准。该委员会试图确保修订后的标准足够灵活，既可用于一般医疗保健提供者，而无需获得神经心理学测试，先进的成像和脑脊液测量，也可用于参与研究或临床试验研究的专业研究人员，他们将拥有这些工具。我们提出了全因痴呆和AD痴呆的标准。我们保留了1984年标准中可能的AD痴呆的一般框架。在过去27年经验的基础上，我们对诊断的临床标准进行了一些修改。我们还保留了可能的AD痴呆这个术语，但以比以前更集中的方式重新定义了它。生物标志物证据也被整合到可能和可能的AD痴呆的诊断制剂中，用于研究环境。AD痴呆的核心临床标准将继续成为临床实践中诊断的基石，但生物标志物证据有望提高AD痴呆诊断的病理生理学特异性。未来还有很多工作要做，以验证AD痴呆的生物标志物诊断。
The National Institute on Aging and the Alzheimer’s Association charged a workgroup with the task of revising the 1984 criteria for Alzheimer’s disease (AD) dementia. The workgroup sought to ensure that the revised criteria would be flexible enough to be used by both general healthcare providers without access to neuropsychological testing, advanced imaging, and cerebrospinal fluid measures, and specialized investigators involved in research or in clinical trial studies who would have these tools available. We present criteria for all-cause dementia and for AD dementia. We retained the general framework of probable AD dementia from the 1984 criteria. On the basis of the past 27 years of experience, we made several changes in the clinical criteria for the diagnosis. We also retained the term possible AD dementia, but redefined it in a manner more focused than before. Bio-marker evidence was also integrated into the diagnostic formulations for probable and possible AD dementia for use in research settings. The core clinical criteria for AD dementia will continue to be the cornerstone of the diagnosis in clinical practice, but biomarker evidence is expected to enhance the pathophysiological specificity of the diagnosis of AD dementia. Much work lies ahead for validating the biomarker diagnosis of AD dementia.
登录
查看更多内容
影响因子：
158.5
作者：
Mayeux, R;Saunders, AM;Phelps, CH
通讯作者：
Phelps, CH
DOI：
10.1016/j.jalz.2011.03.004
发表时间：
2011-05
期刊：
Alzheimer's & dementia : the journal of the Alzheimer's Association
影响因子：
--
作者：
Jack CR Jr;Albert MS;Knopman DS;McKhann GM;Sperling RA;Carrillo MC;Thies B;Phelps CH
通讯作者：
Phelps CH
影响因子：
14.5
作者：
Dolan, David;Troncoso, Juan;O'Brien, Richard J.
通讯作者：
O'Brien, Richard J.
DOI：
10.1016/j.jalz.2011.03.008
发表时间：
2011-05
期刊：
Alzheimer's & dementia : the journal of the Alzheimer's Association
影响因子：
--
作者：
Albert MS;DeKosky ST;Dickson D;Dubois B;Feldman HH;Fox NC;Gamst A;Holtzman DM;Jagust WJ;Petersen RC;Snyder PJ;Carrillo MC;Thies B;Phelps CH
通讯作者：
Phelps CH
影响因子：
9.9
作者：
MCKHANN, G;DRACHMAN, D;STADLAN, EM
通讯作者：
STADLAN, EM